Histrelin (Supprelin LA, Vantas)
Histrelin Acetate (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-N-tau-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide diacetate)
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved small implant placed under the skin that slowly releases medication over 12 months. It is sold as Supprelin LA to pause early puberty in children, and as Vantas to lower testosterone in men with advanced prostate cancer.
Safety Summary
In the CPP clinical trials (n=47), the most common adverse reactions involved the implant site: bruising (51%), pain (40%), soreness (32%), erythema (23%), swelling (17%) (FDA Supprelin LA label). Serious adverse reactions in the 12-month study included seizure in one patient and pituitary tumor (benign) in another. In the long-term extension, serious adverse reactions included depression (n=1), aggression (n=2), and one death from acute bronchopneumonia and Dravet syndrome (not drug-related). In prostate cancer patients (n=171 up to 24 months), hot flashes were the most common event (65.5%), followed by fatigue (9.9%), implant site reaction (5.8%), testicular atrophy (5.3%), gynecomastia (4.1%), erectile dysfunction (3.5%), constipation (3.5%), headache (2.9%), insomnia (2.9%), decreased libido (2.3%), renal impairment (4.7%), and weight increase (2.3%) (Vantas Canadian label). Post-marketing reports for GnRH agonists include pseudotumor cerebri, psychiatric events, convulsions, and severe cutaneous adverse reactions (FDA label 2025). Across indications, local procedural problems and expected endocrine effects dominate the safety profile.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-9]